School of Medicine


Showing 481-490 of 1,299 Results

  • Mona D. Shah, MD, MBA

    Mona D. Shah, MD, MBA

    Adjunct Clinical Associate Professor, Pediatrics - Hematology & Oncology

    BioDr. Mona Shah is a pediatric hematologist-oncologist, who earned her MD degree at the University of Maryland in 2001. She completed both her categorical pediatrics and global health residencies in 2004, followed by a pediatric hematology-oncology fellowship in 2007. She earned her MS in Clinical Investigation as part of the Clinical Scientist Training Program (CSTP) at Baylor College of Medicine in 2011, and more recently, completed an Executive MBA at Rice University Jones School of Business in 2018.

    Dr. Shah was an Associate Professor at Baylor College of Medicine (2007 - 2020) in both Pediatrics and Medicine, local site PI on a number of pediatric hemostasis/thrombosis clinical trials, and spent 10 years as an Associate Medical Director of Clinical Operations, Quality, and Safety at Texas Children’s Hospital, Houston, TX.

    Dr. Shah joined Genentech (a Member of the Roche Group)’s Rare Blood Disorders Franchise (Product Development - Oncology-Hematology) in February 2020, quickly advancing to Lead Medical Director, where she served as Medical Monitor for 2 Phase III Clinical Trials (crovalimab in atypical hemolytic uremic syndrome, aHUS). She was also engaged with the Renal Franchise (I2O) in developing crovalimab in Lupus Nephritis (Phase I & II Clinical Trials in development), and with Human Factors/Pediatric Formulations Working Group on autoinjector devices and oral formulations.

    After completing a rotation in Early Development Safety (EDS), she was promoted to Senior Medical Safety Director in Late Stage Product Development, and was appointed Safety Strategy Lead for giredestrant in early and metastatic breast, ovarian, and endometrial cancer global clinical trials. She has experience in innovative study designs (adaptive/multi-drug), with FDA/EMA pediatric investigational plans, and health authority interactions. In June 2023, she was appointed Pediatric Safety Lead, in collaboration with the iPODD Team, supporting safety for pediatric indications and devices, and serves as the Co-Chair of the Pediatric Safety Expert Group.

    Dr. Shah has kept and completed a bucket list since she was 7 years old (keeps growing): Running wild bouldering/rock climbing as a child in the Shenandoah/Blue Ridge Mountains, swimming with dolphins/piranhas in the Amazon, climbing inside a volcano caldera in Iceland, snorkeling the Great Barrier Reef ... have passport/will travel!

    Since July 2022, she has joined Stanford University School of Medicine, as an Adjunct Clinical Associate Professor in the Department of Pediatrics, Division of Hematology-Oncology, where she enjoys teaching MSII students, and at the bedside in the Lucille Packard Bass Center Hematology Clinic. Dr. Shah enjoys free time in her new home base near San Francisco, where she hosts her visiting parents, friends, and extended family.

  • Neha Shah

    Neha Shah

    Clinical Assistant Professor, Medicine - Immunology & Rheumatology

    BioDr Shah's clinical and research interests lie in Integrative Rheumatology, healing-oriented medicine that takes account of the whole patient, including all aspects of lifestyle. It emphasizes the therapeutic relationship between practitioner and patient, is informed by evidence, and makes use of all appropriate therapies, including those outside the realm of allopathic medicine. Specifically, she is interested in exploring the impact of diet/nutrition/botanicals on inflammation as it pertains to rheumatic diseases such as gout, rheumatoid arthritis, lupus, psoriatic arthritis and other autoimmune conditions, as well as studying the impact of other lifestyle approaches such as mindful meditation, sleep, yoga, stress reduction, etc. on disease burden and quality of life of patients with rheumatic diseases. She boarded in Lifestyle Medicine and has advanced training in Functional Medicine. Dr Shah is currently pursuing additional training in Ayurvedic Medicine.

  • Nigam H. Shah, MBBS, PhD

    Nigam H. Shah, MBBS, PhD

    Professor of Medicine (Biomedical Informatics) and of Biomedical Data Science

    Current Research and Scholarly InterestsWe answer clinical questions using aggregate patient data at the bedside. The Informatics Consult Service (https://greenbutton.stanford.edu/) put this idea in action and led to the creation of Atropos Health. We build predictive models that allow taking mitigating actions, keeping the human in the loop.

  • Nirao Shah

    Nirao Shah

    Professor of Psychiatry and Behavioral Sciences (Major Laboratories and Clinical Translational Neurosciences Incubator), of Neurobiology and, by courtesy, of Obstetrics and Gynecology
    On Leave from 09/23/2024 To 03/15/2025

    Current Research and Scholarly InterestsWe study how our brains generate social interactions that differ between the sexes. Such gender differences in behavior are regulated by sex hormones, experience, and social cues. Accordingly, we are characterizing how these internal and external factors control gene expression and neuronal physiology in the two sexes to generate behavior. We are also interested in understanding how such sex differences in the healthy brain translate to sex differences in many neuro-psychiatric illnesses.

  • Nirav R. Shah, MD, MPH

    Nirav R. Shah, MD, MPH

    Adjunct Professor, Medicine - Primary Care and Population Health

    BioNirav R. Shah, MD, MPH, is Senior Scholar at Stanford University’s School of Medicine. He is a distinguished public health and healthcare leader with experience as an operator, scientist, innovator, and regulator. His expertise spans public health, public and private health insurance, and clinical operations across the continuum of care. At Stanford, Dr. Shah conducts research on improving healthcare quality and safety while lowering cost, driving adoption of digital technologies, and quantitatively evaluating the resulting value for US and international health care systems. Dr. Shah is Board-certified in Internal Medicine and is a graduate of Harvard College and Yale School of Medicine. He is an Advisor to the CDC Director, Senior Fellow of the Institute for Healthcare Improvement (IHI), independent director of STERIS plc [NYSE:STE], and trustee of the John A. Hartford Foundation. Previously, he served as Chief Operating Officer of Kaiser Permanente in Southern California, and as Commissioner of the New York State Department of Health.

  • Ripal Shah

    Ripal Shah

    Clinical Associate Professor, Psychiatry and Behavioral Sciences

    BioRipal Shah, M.D., M.P.H. is a Clinical Associate Professor in the Department of Psychiatry & Behavioral Sciences. She specializes clinically in reproductive psychiatry (the Women's Wellness Clinic - pre-conception, pregnancy, postpartum, breastfeeding, fertility, pre-menstrual dysphoric disorder (PMDD), reproductive and sexual health disorders), lifestyle and integrative approaches to health (the Stanford Center for Integrative Medicine - vitamins, supplements, exercise, behavioral modifications, hypnosis), and in high performers such as physician wellness (the WellConnect program - serving Stanford resident/fellow/faculty physicians). Dr. Shah is regarded as one of the world's experts in PMDD, and one of very few specifically studying PMDD in women of color.

    Her research areas of focus are on women's reproductive psychiatry, integrative approaches to mental health, ethnicity-dependent variability in mental health access and treatment response, psychedelics, spirituality, and minority stress. Her lab also studies the role of Eastern religions on mental health in the U.S., and the connection between Hinduism and psychedelics. Outside of consultations, she specializes in psychotherapy for minority populations, particularly those struggling with issues related to identity (religious identification, racial/ethnic minority stress, racial trauma, professional transitions, changes in family structure or relational status, sexual orientation), as well as cognitive-behavioral therapy for ADHD and anxiety disorders. She has received specialized training in working with Black and South Asian populations.

    While in training at Stanford, she served as Chief Resident and led community partnerships and DEI efforts. She consistently ranked #1 in the Stanford residency (and top 1% in the nation) on the annual knowledge-based examination (PRITE). She is a Disaster Mental Health Responder both domestically and internationally, volunteering after wildfires, hurricanes, and earthquakes. She founded and led the Diversity & Inclusion Advisory Council (DIAC) for psychiatry faculty and residents which is now a model organization for programs across the country, built and then graduated from a Diversity & Health Equity track in the residency, and created the first known Diversity & Health Equity Grand Rounds series. She served as Chair of the Chief Residents’ Council, representing over a thousand physicians to the Stanford Health Care leadership. Before her time at Stanford, she completed an M.P.H. at Harvard University in Health Care Management and Policy, an M.D. from the Mount Sinai School of Medicine in New York with tuition merit scholarship, and a B.S. from Duke University in Economics and Biochemistry.

    She is board certified in Adult Psychiatry, Addiction Medicine, Obesity Medicine, and Integrative Medicine. She pursued additional training in the fields of Emergency Medicine and Internal Medicine, which has informed her evidence-based approach to integrative medicine. She has been credentialed in TMS (transcranial magnetic stimulation), ECT (electroconvulsive therapy), hypnosis, and ketamine infusions. She completed a Certificate in Psychedelic-Assisted Therapies and Research, with training from the Multidisciplinary Association for Psychedelic Studies (MAPS), and also completed MAPS' program MDMA Assisted Therapy Researcher Training. She is on the MDMA Clinical/Monitoring Team for Stanford's Pilot Study of 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Cognitive Behavior Therapy for Obsessive Compulsive Disorder: (MDMA+CBT-4-OCD). She advises several companies and research teams on the clinical use of psychedelics in psychiatry, and often consults with media and tech companies as an industry expert. She has been seen in TIME, Forbes, and the Washington Post, and in 2020 was awarded one of the top 25 rising stars in medicine by Medscape.